Merck & Co., Inc. (MRK) Shares Sold by Nomura Holdings Inc.

Share on StockTwits

Nomura Holdings Inc. trimmed its position in Merck & Co., Inc. (NYSE:MRK) by 99.3% in the fourth quarter, HoldingsChannel.com reports. The firm owned 13,388 shares of the company’s stock after selling 1,896,065 shares during the quarter. Nomura Holdings Inc.’s holdings in Merck & Co., Inc. were worth $1,009,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Vanguard Group Inc. lifted its position in shares of Merck & Co., Inc. by 0.5% during the 3rd quarter. Vanguard Group Inc. now owns 202,833,998 shares of the company’s stock valued at $14,389,044,000 after acquiring an additional 924,701 shares during the last quarter. Vanguard Group Inc lifted its position in shares of Merck & Co., Inc. by 0.5% during the 3rd quarter. Vanguard Group Inc now owns 202,833,998 shares of the company’s stock valued at $14,389,044,000 after acquiring an additional 924,701 shares during the last quarter. BlackRock Inc. lifted its position in shares of Merck & Co., Inc. by 5.6% during the 4th quarter. BlackRock Inc. now owns 194,589,541 shares of the company’s stock valued at $14,868,587,000 after acquiring an additional 10,315,510 shares during the last quarter. Oregon Public Employees Retirement Fund lifted its position in shares of Merck & Co., Inc. by 17,936.7% during the 4th quarter. Oregon Public Employees Retirement Fund now owns 53,150,490 shares of the company’s stock valued at $696,000 after acquiring an additional 52,855,811 shares during the last quarter. Finally, Geode Capital Management LLC lifted its position in shares of Merck & Co., Inc. by 10.4% during the 4th quarter. Geode Capital Management LLC now owns 34,032,366 shares of the company’s stock valued at $2,596,161,000 after acquiring an additional 3,219,877 shares during the last quarter. Hedge funds and other institutional investors own 73.85% of the company’s stock.

Merck & Co., Inc. stock opened at $79.50 on Wednesday. The company has a debt-to-equity ratio of 0.82, a quick ratio of 1.06 and a current ratio of 1.37. The firm has a market cap of $214.35 billion, a price-to-earnings ratio of 18.32, a price-to-earnings-growth ratio of 1.86 and a beta of 0.58. Merck & Co., Inc. has a one year low of $58.03 and a one year high of $83.85.

Merck & Co., Inc. (NYSE:MRK) last posted its earnings results on Tuesday, April 30th. The company reported $1.22 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $1.05 by $0.17. The firm had revenue of $10.82 billion for the quarter, compared to the consensus estimate of $10.45 billion. Merck & Co., Inc. had a net margin of 19.50% and a return on equity of 39.85%. The business’s quarterly revenue was up 7.8% on a year-over-year basis. During the same period in the prior year, the business posted $1.05 earnings per share. On average, sell-side analysts predict that Merck & Co., Inc. will post 4.72 EPS for the current fiscal year.

In other news, major shareholder Merck & Co., Inc. purchased 4,121,683 shares of the firm’s stock in a transaction on Monday, April 8th. The stock was bought at an average cost of $16.00 per share, for a total transaction of $65,946,928.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Robert M. Davis sold 192,572 shares of the company’s stock in a transaction dated Monday, March 25th. The shares were sold at an average price of $82.38, for a total transaction of $15,864,081.36. Following the sale, the executive vice president now owns 330,232 shares of the company’s stock, valued at $27,204,512.16. The disclosure for this sale can be found here. Insiders have sold 538,099 shares of company stock worth $43,923,339 over the last three months. Company insiders own 0.27% of the company’s stock.

Several brokerages have issued reports on MRK. BMO Capital Markets downgraded shares of Merck & Co., Inc. from an “outperform” rating to a “market perform” rating and set a $80.00 target price on the stock. in a research note on Wednesday, January 23rd. Zacks Investment Research downgraded shares of Merck & Co., Inc. from a “strong-buy” rating to a “hold” rating in a research note on Thursday, January 24th. Argus boosted their target price on shares of Merck & Co., Inc. to $95.00 and gave the company a “buy” rating in a research note on Wednesday, February 20th. Cantor Fitzgerald started coverage on shares of Merck & Co., Inc. in a research note on Friday, February 22nd. They set an “overweight” rating and a $95.00 target price on the stock. Finally, ValuEngine downgraded shares of Merck & Co., Inc. from a “buy” rating to a “hold” rating in a research note on Thursday, April 18th. Three equities research analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the stock. Merck & Co., Inc. currently has an average rating of “Buy” and an average price target of $82.92.

TRADEMARK VIOLATION NOTICE: “Merck & Co., Inc. (MRK) Shares Sold by Nomura Holdings Inc.” was posted by Ticker Report and is the sole property of of Ticker Report. If you are reading this news story on another domain, it was illegally copied and republished in violation of U.S. & international copyright and trademark legislation. The original version of this news story can be read at https://www.tickerreport.com/banking-finance/4349028/merck-co-inc-mrk-shares-sold-by-nomura-holdings-inc.html.

Merck & Co., Inc. Profile

Merck & Co, Inc provides healthcare solutions worldwide. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services, and Alliances. The company offers therapeutic and preventive agents to treat cardiovascular, type 2 diabetes, chronic hepatitis C virus, HIV-1 infection, intra-abdominal, fungal infection, insomnia, and inflammatory diseases.

Read More: How does new data get added to a blockchain?

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRK).

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Parsley Energy Sees Unusually High Options Volume
Parsley Energy Sees Unusually High Options Volume
Stock Traders Purchase Large Volume of Western Midstream Partners Put Options
Stock Traders Purchase Large Volume of Western Midstream Partners Put Options
VICI Properties Sees Unusually High Options Volume
VICI Properties Sees Unusually High Options Volume
Traders Purchase Large Volume of Parsley Energy Call Options
Traders Purchase Large Volume of Parsley Energy Call Options
AbbVie Target of Unusually Large Options Trading
AbbVie Target of Unusually Large Options Trading
Eversource Energy Sees Unusually High Options Volume
Eversource Energy Sees Unusually High Options Volume


© 2006-2019 Ticker Report